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Abstract:  3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which 
make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The 
present study investigated the effects of MDMA on extracellular dopamine (DAex) and serotonin (5-HTex) levels in the 
striatum and prefrontal cortex (PFC) using in vivo microdialysis techniques in mice lacking DA transporters (DAT) and/or 
5-HT transporters (SERT). Subcutaneous injection of MDMA (3, 10 mg/kg) significantly increased striatal DAex in wild-
type mice, SERT knockout mice, and DAT knockout mice, but not in DAT/SERT double-knockout mice. The MDMA-
induced increase in striatal DAex in SERT knockout mice was significantly less than in wildtype mice. In the PFC, 
MDMA dose-dependently increased DAex levels in wildtype, DAT knockout, SERT knockout and DAT/SERT double-
knockout mice to a similar extent. In contrast, MDMA markedly increased 5-HTex in wildtype and DAT knockout mice 
and slightly increased 5-HTex in SERT-KO and DAT/SERT double-knockout mice. The results confirm that MDMA acts 
at both DAT and SERT and increases DAex and 5-HTex. 
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INTRODUCTION 
  3,4-Methylendioxymethamphetamine (MDMA, street 
name: ecstasy) exhibits both stimulatory and hallucinogenic 
properties which make its psychoactive effects unique and 
different from those of typical hallucinogens or psychostimu-
lants. Under in vitro conditions, MDMA has been shown to 
increase the release of dopamine (DA), serotonin (5-HT), 
and norepinephrine (NE) from brain slices and prevent the 
reuptake of DA, 5-HT, and NE into brain synaptosomes [1-
4]. MDMA binds with higher affinity to the 5-HT transporter 
(SERT) than to the DA transporter (DAT) [5, 6] and pro-
duces a greater release of 5-HT than DA [7-9]. 
 In  vivo microdialysis studies have revealed that systemic 
injection of MDMA increases extracellular levels of DA and 
5-HT in the striatum and prefrontal cortex (PFC) [7, 10-13]. 
MDMA induces DA release, at least in the striatum, through 
several mechanisms. For example, the release of DA elicited 
by MDMA is hypothesized to involve both transporter- [14, 
15] and impulse-dependent processes [8]. Additionally, the 
increased 5-HT function resulting from MDMA-induced 5-
HT release has been suggested to stimulate 5-HT2 receptors, 
thereby further enhancing DA release [11, 16, 17]. 
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  Monoamine transporter knockout (KO) mice provide 
useful in vivo models to analyze the effects of psychoactive 
drugs. In SERT-KO mice, Begels et al. (1998) reported a 
lack of locomotor-stimulating effects of MDMA [18]. 
MDMA self-administration is also absent in SERT-KO mice 
[13]. Moreover, the ability of MDMA administration to in-
duce  -aminobutyric acid transporter 1 expression in the 
frontal cortex and midbrain was reduced in SERT-KO mice 
[19]. In contrast, DAT-KO mice are hyperactive [20, 21] and 
display perseverative locomotor patterns [22]. MDMA   
decreases hyperactivity and potentiates the perseverative 
pattern of locomotor activity in DAT-KO mice [23]. How-
ever, the mechanisms underlying these MDMA effects have 
not been sufficiently elucidated. 
  To clarify the action of MDMA on the DAT or SERT in 
the striatum and PFC, we investigated the effects of MDMA 
on extracellular levels of DA (DAex) and 5-HT (5-HTex) us-




  Wildtype and DAT-KO mouse littermates from crosses 
of heterozygous/heterozygous DAT-KO mice on a 129/C57 
mixed genetic background served as subjects. SERT-KO and 
DAT/SERT double-KO mouse littermates from crosses of 
heterozygous DAT/homozygous SERT knockout mice on a 
129/C57 mixed genetic background also served as subjects. 92    Current Neuropharmacology, 2011, Vol. 9, No. 1  Hagino et al. 
The experimental procedures and housing conditions were 
approved by the Institutional Animal Care and Use Commit-
tee of Tokyo Institute of Psychiatry, and all animals were 
cared for and treated humanely in accordance with our   
institutional animal experimentation guidelines. Naive adult 
mice were housed in an animal facility maintained at 22 ± 
2°C and 55 ± 5% relative humidity under a 12 h light/dark 
cycle with lights on at 8:00 a.m. and off at 8:00 p.m. Food 
and water were available ad libitum. In microdialysis   
experiments, male and female mice from 10 to 24 weeks   
old were examined. 
Surgery and Microdialysis Procedure 
  Mice were stereotaxically implanted, under sodium pen-
tobarbital anesthesia (50 mg/kg, intraperitoneally), with mi-
crodialysis probes in the striatum (anterior +0.6 mm, lateral 
+1.8 mm, ventral -4.0 mm from bregma) or PFC (anterior 
+2.0 mm, lateral +0.5 mm, ventral -3.0 mm from bregma), 
according to the atlas of Franklin and Paxinos [24]. Twenty-
four hours after implantation, the dialysis experiments were 
performed in freely-moving animals. Evaluation of DAex and 
5-HTex has been previously described [25]. Basal levels of 
DAex and 5-HTex were obtained from average concentrations 
of three consecutive samples when they were stable. 
Drugs 
  Drugs were dissolved in saline and administered subcu-
taneously (s.c.) in a volume of 10 ml/kg. MDMA (3 and 10 
mg/kg) was administered after establishment of stable base-
line, and the dialysate was continuously collected for 180 
min. 
Statistical Analysis 
 DAex and 5-HTex responses to drugs were expressed as  
a percentage of basal levels. Areas under the curve (AUC)  
of DAex and 5-HTex during the 180 min period after drug 
administration were calculated as the effects of drugs.   
AUC values of all groups were analyzed using a two-way 
analysis of variance (ANOVA). Individual post hoc com-
parisons were performed with Fisher’s protected least   
significant difference (PLSD) test. In all cases, the PLSD   
test was applied for multiple comparisons, and values of   
p < 0.05 were considered statistically significant. Data were 
analyzed with Statview J5.0 software (SAS Institute Inc., 
Cary, NC, USA). 
RESULTS 
Baselines of DAex and 5-HTex in the Striatum and PFC 
  The baselines of DAex and 5-HTex in the striatum and 
PFC are shown in Table 1. As previously reported [25], 
baselines of DAex in the striatum were significantly higher in 
DAT-KO and DAT/SERT-double KO mice than in wildtype 
mice (one-way ANOVA; F3,66 = 37.708, p < 0.001). Base-
lines of DAex in the PFC were not different between wild-
type, DAT-KO, SERT-KO, and DAT/SERT double-KO 
mice (one-way ANOVA; F3,76 = 0.291, p = 0.832). Baselines 
of 5-HTex were significantly higher in SERT-KO and 
DAT/SERT double-KO mice than in wildtype mice in both 
the striatum (one-way ANOVA; F3,66 = 37.716, p < 0.001) 
and PFC (one-way ANOVA; F3,76 = 47.715, p < 0.001). 
Effects of MDMA on DAex and 5-HTex in the Striatum 
  MDMA (3 and 10 mg/kg) dose-dependently increased 
DAex in wildtype and SERT-KO mice, but not in DAT/SERT 
double-KO mice (Fig. 1A, B). Two-way ANOVA (drug  
genotype) of the DAex AUC calculated during the 180 min 
posttreatment period revealed significant effects of drug 
(F2,58 = 94.751, p < 0.001) and genotype (F3,58 = 26.775, p < 
0.001) and a significant drug  genotype interaction (F6,58 = 
21.352, p < 0.001). Post hoc comparisons revealed that the 
effects of MDMA (10 mg/kg) on DAex in SERT-KO mice 
was significantly less than in wildtype mice (p  < 0.001; 
Fisher’s PLSD post hoc test). However, DAT-KO mice ex-
hibited significant MDMA (10 mg/kg)-induced increases in 
DAex levels (p < 0.001; Fisher’s PLSD post hoc test), in-
creases that were less than in wildtype mice (p  < 0.001; 
Fisher’s PLSD post hoc test). MDMA (3 and 10 mg/kg) 
dose-dependently increased 5-HTex in wildtype and DAT-
KO mice (Fig. 1C, D). Two-way ANOVA (drug  genotype) 
of 5-HTex revealed significant effects of drug (F2,58 = 23.578, 
p < 0.001) and genotype (F3,58 = 21.589, p < 0.001) and a 
significant drug  genotype interaction (F6,58 = 7.769, p < 
0.001). The effects of MDMA (3 and 10 mg/kg) on 5-HTex 
in DAT-KO mice was significantly higher than in wildtype 
mice (p < 0.05 and p  < 0.01, respectively; Fisher’s PLSD 
post hoc test). When the effects of MDMA were analyzed 
only in SERT-KO and DAT/SERT double-KO mice, two-
way ANOVA (drug  genotype) of 5-HTex revealed a   
significant effect of drug (F2,25 = 11.858, p < 0.001) but no 
effect of genotype (F1,25 = 0.492, p = 0.489) and no drug  
genotype interaction (F2,25 = 2.773, p = 0.082). The effects of 
Table 1.  The Baselines (fmol/10 min) of DAex and 5-HTex in the Striatum and PFC 
 Striatum  PFC 
Genotype n  DAex 5-HTex n DAex 5-HTex 
Wildtype  20  43.00 ± 5.15  1.24 ± 0.17  24  1.24 ± 0.18  1.87 ± 0.20 
DAT-KO  19  486.26 ± 62.00
***   1.01 ± 0.13  21  1.16 ± 0.16  1.87 ± 0.24 
SERT-KO  16  56.18 ± 7.44  13.07 ± 1.97
***  16  1.32 ± 0.28  15.09 ± 1.73
*** 
DAT/SERT-KO  15  596.18 ± 73.38
***  15.13 ± 1.91
***  19  1.42 ± 0.22  12.21 ± 1.43
*** 
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MDMA (10 mg/kg) on 5-HTex in DAT/SERT double-KO 
mice was significantly less than in SERT-KO mice   
(p < 0.05; Fisher’s PLSD post hoc test). 
Effects of MDMA on DAex and 5-HTex in the PFC 
  MDMA (3 and 10 mg/kg) dose-dependently increased 
DAex in wildtype, DAT-KO, SERT-KO, and DAT/SERT 
double-KO mice (Fig. 2A, B). Two-way ANOVA (drug  
genotype) of DAex revealed a significant effect of drug (F2,68 
= 53.368, p < 0.001) but no effect of genotype (F3,68 = 0.203, 
p = 0.894) and no drug  genotype interaction (F6,68 = 0.408, 
p = 0.871). MDMA (3 and 10 mg/kg) dose-dependently in-
creased 5-HTex in wildtype and DAT-KO mice (Fig. 2C, D). 
Two-way ANOVA (drug  genotype) of 5-HTex revealed 
significant effects of drug (F2,68 = 32.357, p < 0.001) and 
genotype (F3,68 = 19.078, p < 0.001) and a significant drug  
genotype interaction (F6,68 = 10.596, p < 0.001). The effect 
of MDMA (10 mg/kg) on 5-HTex in DAT-KO mice was sig-
nificantly less than in wildtype mice (p  < 0.01; Fisher’s 
PLSD post hoc test). When the effects of MDMA were ana-
lyzed only in SERT-KO and DAT/SERT double-KO mice, 
two-way ANOVA (drug  genotype) of 5-HTex revealed a 
significant effect of drug (F2,29 = 28.906, p < 0.001) but no 
significant effect of genotype (F1,29 = 0.236, p = 0.631) and 
no drug  genotype interaction (F2,29 = 0.609, p =0.551). 
DISCUSSION 
 MDMA  increased  DAex and 5-HTex in the striatum and 
PFC, consistent with several previous microdialysis studies 
[7, 10-13]. In DAT/SERT double-KO mice, MDMA did not 
increase DAex in the striatum, and the increases in 5-HTex 
were minimal in the striatum and PFC. These results confirm 
that MDMA acts at both the DAT and SERT. 
 MDMA  increased  DAex in wildtype and SERT-KO mice, 
but not in DAT/SERT double-KO mice. In the absence of the 
DAT, MDMA-induced changes in DAex were smaller than in 
wildtype mice. Therefore, the DAT is likely mainly involved 
in the changes in DAex induced by MDMA. Although DAT-
KO mice exhibited significant MDMA-induced increases in 
DAex levels, these increases were less than in wildtype mice. 
The increase in DAex produced by MDMA in DAT-KO mice 
may have two possible explanations. One possibility is that 
elevated 5-HTex levels produced by MDMA may influence 
DA release. Microdialysis studies have shown that MDMA, 
by increasing 5-HTex, indirectly increases DAex via an action 
at 5-HT2  receptors [7, 8, 17]. Another possibility is that 
MDMA inhibits DA uptake into 5-HT axon terminals and 
increases DAex. The SERT is able to transport DA into 5-HT 
cells [26, 27], and the selective SERT blocker fluoxetine 
















Fig. (1). Effects of MDMA on DAex and 5-HTex in the striatum in wildtype, DAT-KO, SERT-KO, and DAT/SERT double-KO mice. (A, C) 
Temporal pattern of DAex and 5-HTex before and after injection with saline or MDMA (3 and 10 mg/kg, s.c.). The arrows indicate drug injec-
tion time. Each point represents the mean ± SEM of the percentage of DAex or 5-HTex baselines. (B, D) Histogram representing the mean 
AUC (± SEM) of DAex or 5-HTex during the 180 min period after injection with saline or MDMA (n = 4-8). *p < 0.05, ***p < 0.001, com-
pared with saline group of the same genotype; 
#p < 0.05, 
##p < 0.01, 
###p < 0.001, compared with corresponding wildtype data in the same 
drug treatment (two-way ANOVA followed by Fisher’s PLSD post hoc test). 94    Current Neuropharmacology, 2011, Vol. 9, No. 1  Hagino et al. 
  Microdialysis studies have shown that NET inhibitors 
increased DAex in the PFC [28, 29], suggesting that NET can 
influence DA neurotransmission. Moron et al. (2002) re-
ported that DA uptake in the PFC depends primarily on the 
NET [30]. This study showed a similar basal extracellular 
DA concentration in the PFC in DAT-KO and wildtype 
mice. DAex in the PFC is regulated by the NET. MDMA 
dose-dependently increased DAex  in wildtype, DAT-KO, 
SERT-KO, and DAT/SERT double-KO mice. Therefore, 
MDMA may act at the NET and increase DAex levels in the 
PFC. 
  MDMA slightly increased 5-HTex in the striatum and 
PFC in mice lacking the SERT. The selective DAT blocker 
GBR12909 produced a substantial increase in dialysate 5-HT 
in SERT-KO mice that was not found in wildtype mice [25]. 
When the SERT is disrupted in SERT-KO mice, 5-HT is 
found in DA neurons in the substantia nigra and ventral teg-
mental area [31]. The DAT appears to play a compensatory 
role in 5-HT uptake in SERT-KO mice. Therefore, MDMA 
may act at the DAT and increase 5-HTex levels in the stria-
tum in SERT-KO mice. The NET also appears to be able to 
play a role in 5-HT uptake [32]. In the PFC, MDMA may 
increase 5-HTex levels by acting at the NET in SERT-KO 
mice. 
  MDMA markedly increased 5-HTex in wildtype and 
DAT-KO mice. MDMA binds with higher affinity to the 
SERT than to the DAT [5, 6]. Consistent with in vitro re-
sults, MDMA produced greater elevations in 5-HT than DA. 
Relevant studies have shown that many of the subjective 
effects of MDMA in human volunteers are reduced after 
administration of a 5-HT2 receptor antagonist or 5-HT reup-
take inhibitors, suggesting that these effects are dependent on 
SERT-mediated enhancement of serotonergic transmission 
[33, 34]. 
  In conclusion, the present microdialysis study using 
DAT- and/or SERT-KO mice demonstrated that MDMA 
targets monoamine transporters and stimulates predomi-
nantly serotonergic transmission. 
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Fig. (2). Effects of MDMA on DAex and 5-HTex in the PFC in wildtype, DAT-KO, SERT-KO, and DAT/SERT double-KO mice. (A, C) 
Temporal pattern of DAex or 5-HTex before and after injection with saline or MDMA (3 and 10 mg/kg, s.c.). The arrows indicate drug injec-
tion time. Each point represents the mean ± SEM of the percentage of DAex or 5-HTex baselines. (B, D) Histogram representing the mean 
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